Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Rebecca Hong
Observed names:
R Hong,
Rebecca Hong Thibodeau,
Thibodeau, Rebecca Hong
Institution:
Genentech
Observed institutions:
Genentech,
Array BioPharma (United States)
OpenAlex ID:
A5085127849
MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade
2016
·
Peter J.R. Ebert
, Jeanne Cheung
, et al.
·
Immunity
·
766
PDF
Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors
2015
·
Anneleen Daemen
, David Peterson
, et al.
·
Proceedings of the National Academy of Sciences
·
446
Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice
2017
·
Janet Lau
, Jeanne Cheung
, et al.
·
Nature Communications
·
394
PDF
Targeting Activated Akt with GDC-0068, a Novel Selective Akt Inhibitor That Is Efficacious in Multiple Tumor Models
2013
·
Jie Lin
, Deepak Sampath
, et al.
·
Clinical Cancer Research
·
324
Metabolic plasticity underpins innate and acquired resistance to LDHA inhibition
2016
·
Aaron Boudreau
, Hans E Purkey
, et al.
·
Nature Chemical Biology
·
301
Discovery of GDC-0077 (Inavolisib), a Highly Selective Inhibitor and Degrader of Mutant PI3Kα
2022
·
Emily J. Hanan
, Marie-Gabrielle Braun
, et al.
·
Journal of Medicinal Chemistry
·
180
The Kinase Activity of Hematopoietic Progenitor Kinase 1 Is Essential for the Regulation of T Cell Function
2018
·
Sairy Hernandez
, Jing Qing
, et al.
·
Cell Reports
·
135
PDF
Pan-Cancer Metabolic Signature Predicts Co-Dependency on Glutaminase and De Novo Glutathione Synthesis Linked to a High-Mesenchymal Cell State
2018
·
Anneleen Daemen
, Bonnie Liu
, et al.
·
Cell Metabolism
·
89
PDF
Bcl-2/Bcl-xL Inhibition Increases the Efficacy of MEK Inhibition Alone and in Combination with PI3 Kinase Inhibition in Lung and Pancreatic Tumor Models
2013
·
Nguyen Tan
, Maureen Wong
, et al.
·
Molecular Cancer Therapeutics
·
86
Abstract PD4-14: GDC-0077 is a selective PI3Kalpha inhibitor that demonstrates robust efficacy in PIK3CA mutant breast cancer models as a single agent and in combination with standard of care therapies
2018
·
R Hong
, K Edgar
, et al.
·
Cancer Research
·
29
Preclinical assessment of the PI3Kα selective inhibitor inavolisib and prediction of its pharmacokinetics and efficacious dose in human
2024
·
Laurent Salphati
, Jodie Pang
, et al.
·
Xenobiotica
·
19
Abstract 156: Preclinical characterization of GDC-0077, a specific PI3K alpha inhibitor in early clinical development
2017
·
Kyle Edgar
, Emily Hanan
, et al.
·
Cancer Research
·
18
Abstract S6-04: The PI3K inhibitor, taselisib, has enhanced potency in PIK3CA mutant models through a unique mechanism of action
2017
·
LS Friedman
, KA Edgar
, et al.
·
Cancer Research
·
9
Abstract P3-11-23: GDC-0077 is a selective PI3K alpha inhibitor with robust efficacy in PIK3CA mutant hormone-positive breast cancer models
2020
·
Kyle Edgar
, Rebecca Hong
, et al.
·
Cancer Research
·
8
Abstract 370: The PI3K inhibitor, taselisib (GDC-0032), has enhanced potency in PIK3CA mutant models through a unique mechanism of action
2016
·
Kyle A. Edgar
, Kyung Song
, et al.
·
Cancer Research
·
7
Abstract 146: The PI3K inhibitor, taselisib, has a unique mechanism of action that leads to enhanced potency in PIK3CA mutant models
2017
·
Kyung W. Song
, Kyle A. Edgar
, et al.
·
Cancer Research
·
6
Abstract 964: Inhibiting glycolysis with an LDHA inhibitor: A new solution to an old problem
2014
·
Thomas O'Brien
, Hans Purkey
, et al.
·
Cancer Research
·
3
Abstract 873: Combined targeting of Akt and MEK with the Akt inhibitor GDC-0068 and MEK inhibitor GDC-0973 demonstrates synergistic anti-tumor effects
2012
·
Michelle A. Nannini
, Rebecca Hong
, et al.
·
Cancer Research
·
2
Abstract 2672: Characterization of the enhanced potency of PI3K inhibitor taselisib (GDC-0032) in PI3K mutant cell lines and models
2015
·
Kyle A. Edgar
, Michelle Nannini
, et al.
·
Cancer Research
·
1
Figure S5 from RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy
2025
·
Kyung W. Song
, Kyle A. Edgar
, et al.
PDF
Figure S2 from RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy
2025
·
Kyung W. Song
, Kyle A. Edgar
, et al.
PDF
Figure S1 from RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy
2025
·
Kyung W. Song
, Kyle A. Edgar
, et al.
PDF
Figure S4 from RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy
2025
·
Kyung W. Song
, Kyle A. Edgar
, et al.
PDF
Figure S3 from RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy
2025
·
Kyung W. Song
, Kyle A. Edgar
, et al.
PDF
Figure S6 from RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy
2025
·
Kyung W. Song
, Kyle A. Edgar
, et al.
PDF
Show more works
View as search
Works count:
53
Citation count:
2,823
H-index:
12
I10-index:
12
Year
Topic
Type